-
1
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
Mattheus, M.7
Devins, T.8
Johansen, O.E.9
Woerle, H.J.10
-
2
-
-
85023777061
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925
-
(2017)
N Engl J Med
, vol.377
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
De Zeeuw, D.4
Fulcher, G.5
Erondu, N.6
Shaw, W.7
Law, G.8
Desai, M.9
Matthews, D.R.10
-
3
-
-
85060042753
-
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
-
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, DECLARE-TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019 380 347 357. doi: 10.1056/NEJMoa1812389
-
(2019)
N Engl J Med
, vol.380
, pp. 347-357
-
-
Wiviott, S.D.1
Raz, I.2
Bonaca, M.P.3
Mosenzon, O.4
Kato, E.T.5
Cahn, A.6
Silverman, M.G.7
Zelniker, T.A.8
Kuder, J.F.9
Murphy, S.A.10
-
4
-
-
85034212680
-
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: A subanalysis of EMPA-REG OUTCOME
-
Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, George JT, Zinman B, Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 2018 137 405 407. doi: 10.1161/CIRCULATIONAHA.117.032031
-
(2018)
Circulation
, vol.137
, pp. 405-407
-
-
Verma, S.1
Mazer, C.D.2
Al-Omran, M.3
Inzucchi, S.E.4
Fitchett, D.5
Hehnke, U.6
George, J.T.7
Zinman, B.8
-
5
-
-
85047121888
-
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME® randomised trial
-
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B, Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia 2018 61 1712 1723. doi: 10.1007/s00125-018-4644-9
-
(2018)
Diabetologia
, vol.61
, pp. 1712-1723
-
-
Verma, S.1
Mazer, C.D.2
Fitchett, D.3
Inzucchi, S.E.4
Pfarr, E.5
George, J.T.6
Zinman, B.7
-
6
-
-
85066483412
-
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
-
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019 380 2295 2306. doi: 10.1056/NEJMoa1811744
-
(2019)
N Engl J Med
, vol.380
, pp. 2295-2306
-
-
Perkovic, V.1
Jardine, M.J.2
Neal, B.3
Bompoint, S.4
Heerspink, H.J.L.5
Charytan, D.M.6
Edwards, R.7
Agarwal, R.8
Bakris, G.9
Bull, S.10
-
7
-
-
85030655315
-
The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: The search for the sweet spot in heart failure
-
Verma S, McMurray JJV, Cherney DZI, The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2017 2 939 940. doi: 10.1001/jamacardio.2017.1891
-
(2017)
JAMA Cardiol
, vol.2
, pp. 939-940
-
-
Verma, S.1
McMurray, J.J.V.2
Cherney, D.Z.I.3
-
8
-
-
85060373069
-
Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: A systematic review of data from preclinical studies
-
Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D, Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res 2019 115 266 276. doi: 10.1093/cvr/cvy295
-
(2019)
Cardiovasc Res
, vol.115
, pp. 266-276
-
-
Chin, K.L.1
Ofori-Asenso, R.2
Hopper, I.3
Von Lueder, T.G.4
Reid, C.M.5
Zoungas, S.6
Wang, B.H.7
Liew, D.8
-
9
-
-
85052558182
-
SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review
-
Verma S, McMurray JJV, SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018 61 2108 2117. doi: 10.1007/s00125-018-4670-7
-
(2018)
Diabetologia
, vol.61
, pp. 2108-2117
-
-
Verma, S.1
McMurray, J.J.V.2
-
10
-
-
0032212316
-
Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
-
Haider AW, Larson MG, Benjamin EJ, Levy D, Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998 32 1454 1459. doi: 10.1016/s0735-1097(98)00407-0
-
(1998)
J Am Coll Cardiol
, vol.32
, pp. 1454-1459
-
-
Haider, A.W.1
Larson, M.G.2
Benjamin, E.J.3
Levy, D.4
-
11
-
-
57449107274
-
The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study
-
Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR, The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008 52 2148 2155. doi: 10.1016/j.jacc.2008.09.014
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 2148-2155
-
-
Bluemke, D.A.1
Kronmal, R.A.2
Lima, J.A.3
Liu, K.4
Olson, J.5
Burke, G.L.6
Folsom, A.R.7
-
12
-
-
0026092229
-
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
-
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH, Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991 114 345 352. doi: 10.7326/0003-4819-114-5-345
-
(1991)
Ann Intern Med
, vol.114
, pp. 345-352
-
-
Koren, M.J.1
Devereux, R.B.2
Casale, P.N.3
Savage, D.D.4
Laragh, J.H.5
-
13
-
-
85025434600
-
LV mass independently predicts mortality and need for future revascularization in patients undergoing diagnostic coronary angiography
-
Abdi-Ali A, Miller RJH, Southern D, Zhang M, Mikami Y, Knudtson M, Heydari B, Howarth AG, Lydell CP, James MT, LV mass independently predicts mortality and need for future revascularization in patients undergoing diagnostic coronary angiography. JACC Cardiovasc Imaging 2018 11 423 433. doi: 10.1016/j.jcmg.2017.04.012
-
(2018)
JACC Cardiovasc Imaging
, vol.11
, pp. 423-433
-
-
Abdi-Ali, A.1
Miller, R.J.H.2
Southern, D.3
Zhang, M.4
Mikami, Y.5
Knudtson, M.6
Heydari, B.7
Howarth, A.G.8
Lydell, C.P.9
James, M.T.10
-
14
-
-
0035797832
-
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
-
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S, Heart Outcomes Prevention Evaluation (HOPE) Investigators Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001 104 1615 1621. doi: 10.1161/hc3901.096700
-
(2001)
Circulation
, vol.104
, pp. 1615-1621
-
-
Mathew, J.1
Sleight, P.2
Lonn, E.3
Johnstone, D.4
Pogue, J.5
Yi, Q.6
Bosch, J.7
Sussex, B.8
Probstfield, J.9
Yusuf, S.10
-
15
-
-
4544269713
-
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
-
Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K, Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004 110 1456 1462. doi: 10.1161/01.CIR.0000141573.44737.5A
-
(2004)
Circulation
, vol.110
, pp. 1456-1462
-
-
Devereux, R.B.1
Dahlöf, B.2
Gerdts, E.3
Boman, K.4
Nieminen, M.S.5
Papademetriou, V.6
Rokkedal, J.7
Harris, K.E.8
Edelman, J.M.9
Wachtell, K.10
-
16
-
-
0031006399
-
Left ventricular mass in the elderly. the Cardiovascular Health Study
-
Gardin JM, Arnold A, Gottdiener JS, Wong ND, Fried LP, Klopfenstein HS, O'Leary DH, Tracy R, Kronmal R, Left ventricular mass in the elderly. The Cardiovascular Health Study. Hypertension 1997 29 1095 1103. doi: 10.1161/01.hyp.29.5.1095
-
(1997)
Hypertension
, vol.29
, pp. 1095-1103
-
-
Gardin, J.M.1
Arnold, A.2
Gottdiener, J.S.3
Wong, N.D.4
Fried, L.P.5
Klopfenstein, H.S.6
O'Leary, D.H.7
Tracy, R.8
Kronmal, R.9
-
17
-
-
85053507166
-
Cardiovascular magnetic resonance of cardiac morphology and function: Impact of different strategies of contour drawing and indexing
-
Riffel JH, Schmucker K, Andre F, Ochs M, Hirschberg K, Schaub E, Fritz T, Mueller-Hennessen M, Giannitsis E, Katus HA, Cardiovascular magnetic resonance of cardiac morphology and function: impact of different strategies of contour drawing and indexing. Clin Res Cardiol 2019 108 411 429. doi: 10.1007/s00392-018-1371-7
-
(2019)
Clin Res Cardiol
, vol.108
, pp. 411-429
-
-
Riffel, J.H.1
Schmucker, K.2
Andre, F.3
Ochs, M.4
Hirschberg, K.5
Schaub, E.6
Fritz, T.7
Mueller-Hennessen, M.8
Giannitsis, E.9
Katus, H.A.10
-
18
-
-
84928005641
-
Normal values for cardiovascular magnetic resonance in adults and children
-
Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, Plein S, Tee M, Eng J, Bluemke DA, Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015 17 29. doi: 10.1186/s12968-015-0111-7
-
(2015)
J Cardiovasc Magn Reson
, vol.17
, pp. 29
-
-
Kawel-Boehm, N.1
Maceira, A.2
Valsangiacomo-Buechel, E.R.3
Vogel-Claussen, J.4
Turkbey, E.B.5
Williams, R.6
Plein, S.7
Tee, M.8
Eng, J.9
Bluemke, D.A.10
-
21
-
-
85056869824
-
Can we DECLARE a victory against cardio-renal disease in diabetes?
-
Connelly KA, Bhatt DL, Verma S, Can we DECLARE a victory against cardio-renal disease in diabetes? Cell Metab 2018 28 813 815. doi: 10.1016/j.cmet.2018.11.010
-
(2018)
Cell Metab
, vol.28
, pp. 813-815
-
-
Connelly, K.A.1
Bhatt, D.L.2
Verma, S.3
-
22
-
-
84991106931
-
Empagliflozin's fuel hypothesis: Not so soon
-
Lopaschuk GD, Verma S, Empagliflozin's fuel hypothesis: not so soon. Cell Metab 2016 24 200 202. doi: 10.1016/j.cmet.2016.07.018
-
(2016)
Cell Metab
, vol.24
, pp. 200-202
-
-
Lopaschuk, G.D.1
Verma, S.2
-
23
-
-
85006172812
-
Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: An important clue to the EMPA-REG OUTCOME trial?
-
Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016 39 e212 e213. doi: 10.2337/dc16-1312
-
(2016)
Diabetes Care
, vol.39
, pp. e212-e213
-
-
Verma, S.1
Garg, A.2
Yan, A.T.3
Gupta, A.K.4
Al-Omran, M.5
Sabongui, A.6
Teoh, H.7
Mazer, C.D.8
Connelly, K.A.9
-
24
-
-
85027545481
-
Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure
-
Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PWM, Verma S, Dyck JRB, Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2017 2 347 354. doi: 10.1016/j.jacbts.2017.07.003
-
(2017)
JACC Basic Transl Sci
, vol.2
, pp. 347-354
-
-
Byrne, N.J.1
Parajuli, N.2
Levasseur, J.L.3
Boisvenue, J.4
Beker, D.L.5
Masson, G.6
Fedak, P.W.M.7
Verma, S.8
Dyck, J.R.B.9
-
25
-
-
85073678741
-
24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA study
-
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, Uchiyama K, Niijima Y, Katsuya T, Urata H, 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation 2019 139 2089 2097. doi: 10.1161/CIRCULATIONAHA.118.037076
-
(2019)
Circulation
, vol.139
, pp. 2089-2097
-
-
Kario, K.1
Okada, K.2
Kato, M.3
Nishizawa, M.4
Yoshida, T.5
Asano, T.6
Uchiyama, K.7
Niijima, Y.8
Katsuya, T.9
Urata, H.10
-
26
-
-
85015822587
-
Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis
-
Xing F, Chen J, Zhao B, Jiang J, Tang A, Chen Y, Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis. Medicine (Baltimore) 2017 96 e6290. doi: 10.1097/MD.0000000000006290
-
(2017)
Medicine (Baltimore)
, vol.96
, pp. e6290
-
-
Xing, F.1
Chen, J.2
Zhao, B.3
Jiang, J.4
Tang, A.5
Chen, Y.6
-
27
-
-
85045943801
-
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study
-
Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J 2017 38 3308 3317. doi: 10.1093/eurheartj/ehx525
-
(2017)
Eur Heart J
, vol.38
, pp. 3308-3317
-
-
Schmieder, R.E.1
Wagner, F.2
Mayr, M.3
Delles, C.4
Ott, C.5
Keicher, C.6
Hrabak-Paar, M.7
Heye, T.8
Aichner, S.9
Khder, Y.10
-
28
-
-
85061917506
-
Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: A subanalysis of the EMPA-REG OUTCOME trial
-
Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. Diabetes Care 2019 42 e42 e44. doi: 10.2337/dc18-1959
-
(2019)
Diabetes Care
, vol.42
, pp. e42-e44
-
-
Verma, S.1
Mazer, C.D.2
Bhatt, D.L.3
Raj, S.R.4
Yan, A.T.5
Verma, A.6
Ferrannini, E.7
Simons, G.8
Lee, J.9
Zinman, B.10
-
29
-
-
85041180129
-
How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
-
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018 41 356 363. doi: 10.2337/dc17-1096
-
(2018)
Diabetes Care
, vol.41
, pp. 356-363
-
-
Inzucchi, S.E.1
Zinman, B.2
Fitchett, D.3
Wanner, C.4
Ferrannini, E.5
Schumacher, M.6
Schmoor, C.7
Ohneberg, K.8
Johansen, O.E.9
George, J.T.10
-
30
-
-
85025091208
-
Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes
-
Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ, Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 2017 70 704 712. doi: 10.1016/j.jacc.2017.06.016
-
(2017)
J Am Coll Cardiol
, vol.70
, pp. 704-712
-
-
Januzzi, J.L.1
Butler, J.2
Jarolim, P.3
Sattar, N.4
Vijapurkar, U.5
Desai, M.6
Davies, M.J.7
-
31
-
-
85063954068
-
Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus
-
Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B, Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 2019 139 2591 2593. doi: 10.1161/CIRCULATIONAHA.119.040057
-
(2019)
Circulation
, vol.139
, pp. 2591-2593
-
-
Figtree, G.A.1
Rådholm, K.2
Barrett, T.D.3
Perkovic, V.4
Mahaffey, K.W.5
De Zeeuw, D.6
Fulcher, G.7
Matthews, D.R.8
Shaw, W.9
Neal, B.10
-
32
-
-
85067266385
-
Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction
-
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 2019 139 2516 2527. doi: 10.1161/CIRCULATIONAHA.119.039996
-
(2019)
Circulation
, vol.139
, pp. 2516-2527
-
-
Furtado, R.H.M.1
Bonaca, M.P.2
Raz, I.3
Zelniker, T.A.4
Mosenzon, O.5
Cahn, A.6
Kuder, J.7
Murphy, S.A.8
Bhatt, D.L.9
Leiter, L.A.10
-
33
-
-
85067270152
-
The serendipitous story of SGLT2 inhibitors in heart failure
-
Verma S, McMurray JJV, The serendipitous story of SGLT2 inhibitors in heart failure. Circulation 2019 139 2537 2541. doi: 10.1161/CIRCULATIONAHA.119.040514
-
(2019)
Circulation
, vol.139
, pp. 2537-2541
-
-
Verma, S.1
McMurray, J.J.V.2
|